kt-2000
PARP inhibitors represent the first DDR therapeutic “blockbusters” with multiple FDA-approved products expected to exceed $1B in annual sales.
PARP is a key enzyme involved in sensing and repairing DNA single-strand breaks (SSBs). If SSBs are left unrepaired, the devolve into double-strand breaks (DSBs), which are lethal to the cancer cell.



1 O’Neil, Nature Reviews (2017) Diagrams adapted from Benke, Fronters in Genetics (2012) and Zheng, Biomedicine & Pharmacotherapy (2020)